A Long-Overdue Recognition for Screening Tardive dyskinesia (TD) is a serious, often irreversible drug-induced movement disorder caused by prolonged use of antipsychotic and other dopamine-blocking medications. Despite affecting an estimated 15-50% of patients on antipsychotics, TD remains underdiagnosed – approximately…
As interventional psychiatry scales, many behavioral health operators are encountering a growth constraint. Clinical innovation is accelerating, yet administrative structures remain brittle. This causes friction for both widespread access to care and scalability of advanced therapies like ketamine, TMS, SGB,…
As financial pressure intensifies across healthcare, ambulatory organizations are being forced to rethink how they operate. Rising labor costs, staffing shortages, reimbursement complexity and growing patient expectations have made efficiency no longer optional—but foundational to sustainability. In a recent Becker’s…
Talkiatry today announced $210 million in Series D financing to support the next phase of growth for its nationally scaled, full-stack psychiatry provider. The oversubscribed round was led by Perceptive Advisors, with participation from Sofina and prior lead investors Andreessen…